Skip to main content

ABCD Nationwide Empagliflozin Audit Publications

Papers, abstracts, presentations, posters and webcasts emanating from the audit

Webcast

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at DUK Professional Conference 2022
P230: The effect of sodium-glucose link transporter 2 inhibitors (SGLT2i) on microalbuminuria: cross-class analysis from the ABCD audit programme

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at EASD 2021:
Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and alanine aminotransferase levels (ALT) in the Associated of British Clinical Diabetologists (ABCD) audits - Virtual Meeting | EASD

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at DUK Professional Conference 2021
Comparing the effects of different-sodium glucose link-transporter 2-inhibitors (SGLT2i) on HbA1c an weight in the real world: updated analysis from the Association of British Clinical Diabetologists (ABCD) Audit Programmes

Webcast of an ePoster presentation of the results from the ABCD nationwide SGLT2i audits presented by ABCD audits research fellow, Dr Thomas Crabtree at DUK Professional Conference 2021
The impact of sodium glucose link transporter-2 inhibitors [SGLT2i] on Fib4 score in patients with type 2 diabetes: Analysis using Association of British Clinical Diabetologists [ABCD] nationwide audit data

Webcast of an ePoster presentation of the results from the ABCD nationwide empagliflozin audit presented by ABCD audits research fellow, Dr Thomas Crabtree from Birmingham and Derby, UK, made at the American Diabetes Association virtual meeting in June ADA Virtual 2020 reporting data from the ABCD nationwide audit of empagliflozin in real clinical use in the UK.
Benefits of Empagliflozin Persist in Reduced Renal Function: ABCD Nationwide Empagliflozin Audit

Webcast of an ePoster presentation of the results by Dr Harshal Deshmukh from Hull, UK, made at the American Diabetes Association virtual meeting in June 2020 reporting data from the ABCD nationwide audits of SGLT2 inhibitors in real clinical use in the UK 
Effect Of Raised Alanine Transaminase (ALT) On HbA1c Response to SGLT2 Inhibitors In Type 2 Diabetes

 

Published papers

Thomas SJ Crabtree, Alex Bickerton, Jackie Elliot, Rajeev Raghavan, Dennis Barnes, Siva Sivappriyan, Suzanne Phillips, Alison Evans, Devesh Sennik, Anurita Rohilla, Ian Gallen, Robert EJ Ryder on behalf of the  ABCD Empagliflozin Audit Contributors. Effect of empagliflozin on albuminuria, eGFR and serum creatinine: updated results from the ABCD national empagliflozin audit. British Journal of Diabetes Vol 21 629/951 14 April 2021

https://bjd-abcd.com/index.php/bjd/article/view/629/951

Full Paper

All contributors are listed 
 

Slides from presentations

DUK Professional Conference, Virtual March 2021
EASD 2022 SGLT2 Slides

 

Abstracts

ADA San Fransisco 2019a: Ken Thong, Jonathan Chung-Wah-Cheong, Mahender Yadagiri, Melissa L. Cull, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Devesh K. Sennik, Anurita Rohilla, Hazel Reid, David S. Morris, Marc Atkin, Anthony M. Robinson, David M. Williams, Jeffrey W. Stepehens, Ian W. Gallen, Karen Adamson and Robert E. Ryder. Predictors of Glycaemic and Weight Response to Empagliflozin Treatment: The ABCD Nationwide Empagliflozin Audit. Diabetes 2019 Jun; 68 (Supplement 1): 1200-P. 

ADA San Fransisco 2019b: Ken Thong, Jonathan Chung-Wah-Cheong, Mahender Yadagiri, Melissa L. Cull, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Devesh K. Sennik, Anurita Rohilla, Hazel Reid, David S. Morris, Marc Atkin, Anthony M. Robinson, David M. Williams, Jeffrey W. Stepehens, Ian W. Gallen, Karen Adamson and Robert E. Ryder. Characteristics and Treatment Outcomes of Patients Treated with Empagliflozin in the ABCD Nationwide Empagliflozin Audit. Diabetes 2019 Jun; 68 (Supplement 1): 1201-P. 

ADA Virtual Meeting June 2020a: Thomas S.J. Crabtree, Karen Adamson, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Anthony M. Robinson, Marc Atkin, David S. Morris, David M. Williams, Jeffrey W. Stephens,Devesh K. Sennik, Anurita Rohilla, Melissa L. Cull, Rajeev P. Raghavan, Mahender Yadagiri,Ian W. Gallen and Robert E. Ryder. The Effect of Diabetes Duration on Response to Empagliflozin: Data from the Association of British Clinical Diabetologists (ABCD) Audit Programme.
Diabetes 2020 Jun; 69 (Supplement 1): 2224-PUB.

ADA Virtual Meeting June 2020b: Thomas S.J. Crabtree, Karen Adamson, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Anthony M. Robinson, Marc Atkin, David S. Morris, David M. Williams, Jeffrey W. Stephens,Devesh K. Sennik, Anurita Rohilla, Melissa L. Cull, Rajeev P. Raghavan, Mahender Yadagiri, Ian W. Gallen and Robert E. Ryder. Many Benefits of Empagliflozin Persist in Those with Reduced Renal Function: Updated Data from the Association of British Clinical Diabetologists (ABCD) Audit Programme.
Diabetes 2020 Jun; 69(Supplement 1): 1104-P.

ADA Virtual Meeting, 2020 - Harshal Deshmukh, Alex Bickerton, Suzanne M. Phillips, Alison Evans, Rajeev P. Raghavan, Devesh K. Sennik, Anurita Rohilla, Karen Adamson, Mahender Yadagiri, Ian W. Gallen, Robert E. Ryder and Thozhukat Sathyapalan. Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 Inhibitors (SGLT2i) - Diabetes 2020 Jun; 69(Supplement 1):1110-P

DUK London TC1, 2021 Crabtree, T. S. J., J. Elliott, S. Sivappriyan, D. Barnes, A. Bickerton, I. Gallen, I. Idris, and R. E. J. Ryder. "The impact of sodium glucose link transporter-2 inhibitors (SGLT2i) on Fib4 score in patients with type 2 diabetes: Analysis using Association of British Clinical Diabetologists (ABCD) nationwide audit data." In DIABETIC MEDICINE, vol. 38. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021.

DUK London TC2, 2021 Crabtree, T. S. J., K. Dhatariya, A. Bickerton, S. Sivapanpriy, D. Barnes, S. Tarpey, S. Rowles, K. Adamson, I. Gallen, and R. E. J. Ryder. "Comparing the effects of different sodium-glucose link transporter 2 inhibitors (SGLTi) on HbA1c and weight in the real world: updated analysis from the Association of British Clinical Diabetologists (ABCD) audit programmes." In DIABETIC MEDICINE, vol. 38. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021.

EASD Virtual Meeting, 2021 Gallen, I., T. S. J. Crabtree, A. Gallagher, K. Dhatariya, A. Bickerton, J. Elliott, G. Rayman, and R. E. J. Ryder. "Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and alanine aminotransferase levels (ALT) in the Associated of British Clinical Diabetologists (ABCD) audits." In DIABETOLOGIA, vol. 64, no. SUPPL 1, pp. 218-218. ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES: SPRINGER, 2021.

ADA New Orleans, 2022 Thomas S.J. Crabtree, Alison Gallagher, Siva Sivappriyan, Ketan Dhatariya, Rajeev P. Raghavan, Alex Bickerton, Jackie Elliott, Melissa L. Cull, Gerry Rayman, Ian W. Gallen, Iskandar R. Idris, Robert E. Ryder; 858-P: Predictors of HbA1c and Weight Response to Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) in the Association of British Clinical Diabetologist (ABCD) UK Nationwide Audit. Diabetes 1 June 2022; 71 (Supplement_1): 858–P. https://doi.org/10.2337/db22-858-P

 

Posters 

ADA San Francisco June 2019a
ADA San Francisco June 2019b
ADA Virtual Meeting June 2020TC
ADA Virtual Meeting June 2020HD
ABCD RA Virtual Meeting February 2021TC
Diabetes UK Professional Conference 2021TC
Diabetes UK Professional Conference 2021TC2
ABCD Virtual Meeting October 2021TC
Diabetes UK Professional Conference 2022
ADA 2022

 

The ABCD nationwide empagliflozin audit is an independent audit supported by an unrestricted grant from Boehringer Ingelheim